Blocking a tumor signal made chemo work better in mice
Original title: CCL20-CCR6 Signaling as a Prognostic Biomarker and Therapeutic Target in Temozolomide-Resistant Glioblastoma
How far along is this research?
This is a preprint. Other scientists have not checked it yet, so treat it as an early signal rather than an answer.
This was only tested in lab samples and mice, not in people.
The short version
In lab and mouse tests, blocking one cell signal helped a common brain tumor drug work better.
What was studied. Researchers studied glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, a fast growing brain tumor that often stops responding to the drug temozolomide. They used patient data, tumor cells, lab grown tumor samples, and mice, and tested blocking a cell signal called CCL20-CCR6.
What they found. People whose tumors made less CCL20 lived longer. Temozolomide, alone or with cannabidiol (CBD), pushed CCL20 levels up and did little to the tumors. When the team blocked CCL20 in mice and in lab grown tumor samples, the treatment worked better. Blocking it damaged the tiny power packs inside tumor cells and made the cells die.
What this means, and what it doesn't
What it could mean: This points to a possible way to make temozolomide work better in the future. CCL20 levels might also help doctors judge how a tumor is likely to behave. All of that still needs testing in people.
What it doesn't mean: This is not a treatment you can ask for today. The work was done in cells, in lab grown tumor samples, and in mice, not in people. Many things that work in mice do not work in humans. There is no proof yet that it helps patients live longer, and it is not a cure.
Source: bioRxiv (preprint), August 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.